Medizinische Klinik und Poliklinik I Allgemeine Innere Medizin ...

Dietrich CG, Gartung C, Lorenzen J, Geier A, Wasmuth HE, Matern S, Lammert
F.
Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma.
Ann Hepatol. 2004 Jul-Sep;3(3):118-20.
Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S,
Gartung C.
Consequences of bile duct obstruction on intestinal expression and function of multidrug
resistance-associated protein 2.
Gastroenterology. 2004 Apr;126(4):1044-53.
Ebert O, Wilbert D, Buttgereit P, Ziske C, Flieger D, Schmidt-Wolf IGH.
Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B
lymphoma cells on co-cultured PBMC.
Genet Vaccines Ther. 2004 Oct 14;2(1):15.
Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R,
Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M.
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2
(Abcb4) knockout mice.
Gastroenterology. 2004 Jul;127(1):261-74.
Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL,
Chen F, Stoltenberg E, Spatz K, Hoda F, Cohen DE, Green RM.
Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and
reduces hepatic steatosis.
J Biol Chem. 2004 Jan 23;279(4):2790-9. Epub 2003 Oct 21.
Gehrke R, Brauchle MA, Reifenberg K, Hildt E, Gruetzner U, Schmitz V, Schlicht
HJ, Hofschneider PH, Caselmann WH, Rabe C.
Accumulation of 8-hydroxy-2'-deoxyguanosine adducts in HBx recombinant HepG2
cells and HBx transgenic mice.
Digestion. 2004;70(2):117-26. Epub 2004 Sep 16.
Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, Gartung
C, Lorenzen J, Bosserhoff AK, Brugmann M, Gressner AM, Matern S,
Lammert F.
Common heterozygous hemochromatosis gene mutations are risk factors for inflammation
and fibrosis in chronic hepatitis C.
Liver Int. 2004 Aug;24(4):285-94.
Glasmacher A.
Vancomycin does not benefit persistently febrile neutropenic people with cancer.
European View. Cancer Treat Rev. 2004 Feb;30(1):119-26.
Glasmacher A.
Initial high dose chemotherapy plus autologous stem cell support improves
survival outcomes compared with a standard CHOP regimen in people with higher
intermediate risk aggressive lymphoma.
Cancer Treat Rev. 2004 Oct;30(6):577-82.
107